Amsulostat and Garvan in MRFF funded pancreatic trial
Filed with ASX · · 3 pages · English
• The Garvan Institute of Medical Research secures $3 million MRFF grant funding for two multicentre studies in advanced pancreatic cancer, including one testing Syntara’s amsulostat (SNT-5505) with standard-of- care chemotherapy • Syntara to contribute drug supply plus scientific and clinical expertise, with no cash funding required from the company • The program builds on Garvan’s preclinical re
Earlier from Syntara
- SNT-4728 Phase 2 iRBD Parkinsons UK Trial fully recruited
- Skin scarring program to progress on positive Phase1a result
- Quarterly Shareholder Report and Appendix 4C
- Positive top-line Phase 2a data confirms competitive profile
- Preliminary Final Report
Later from Syntara
- Quarterly Activities/Appendix 4C Cash Flow Report
- Half Year Report and Appendix 4D
- Positive FDA feedback for Amsulostat P2b trial
- Continuation of trading halt
- $8m placement and share purchase plan
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara